Aim of the study
The aim of this case–control study is to evaluate the clinical and biochemical efficiency of Inositol
versus Metformin in polycystic ovary syndrome.
Patients and methods
The 128 patients who completed the study were divided into group A, which included 62 patients prescribed myo-inositol
, two tabs per day, and group B, which included 66 patients prescribed Metformin 1500 mg per day for 3 months. Then, both groups were followed up for 3 months after the end of the treatment period. All patients underwent the following: baseline vaginal ultrasound, BMI and weight evaluation, Anti mullerian hormones (AMH) evaluation, serum progesterone, and Homeostasis Model of Assessment-Insulin Resistance (HOMA-IR), and were evaluated according to clinical and biochemical outcomes.
Spontaneous menstruation and spontaneous pregnancy rate were significantly higher in group A than in group B: 46.7 and 11.2% in the Inositol
group compared with 13.6 and 3.0% in the Metformin group. In terms of weight loss, the difference between both groups was significant in favor of the Inositol
group. A significant difference was also detected in terms of a higher progesterone level in group A, whereas AMH and HOMA-IR showed insignificant differences in both groups.
showed significantly better results in terms of weight reduction, resumption of spontaneous ovulation, and spontaneous pregnancy than Metformin in polycystic ovary syndrome patients. However, the effects of both drugs were comparable in decreasing either AMH or HOMA-IR.